Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701721 | Journal of Thoracic Oncology | 2017 | 23 Pages |
Abstract
Our study showed that salvage SABR provides excellent 5-year OS, local control, and PFS rates with minimal toxicity for patients with isolated NSCLC recurrence in the lung parenchyma. These results are striking and comparable to historically reported outcomes of patients with primary early-stage NSCLC treated with definitive SABR. SABR appears to be a very effective and safe salvage option for patients with isolated lung parenchyma recurrent disease after definitive treatment and should be considered along with surgery as a potential first-line option for patients with local lung parenchymal recurrent disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Bing MD, Eric D. MD, MHS, Ritsuko MD, Zhongxing MD, Melenda MD, Mary MD, PhD, Peter A. PhD, James D. MD, Michael MD, PhD, Daniel MD, Stephen M. MD, Boris MD, David C. MD, John V. MD, PhD, Joe Y. MD, PhD,